As of 2025-07-04, the EV/EBITDA ratio of Pacific Biosciences of California Inc (PACB) is 3.56. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PACB's latest enterprise value is 783.23 mil USD. PACB's TTM EBITDA according to its financial statements is 219.96 mil USD. Dividing these 2 quantities gives us the above PACB EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 15.4x - 17.3x | 16.0x |
| Forward P/E multiples | 19.3x - 22.6x | 20.3x |
| Fair Price | 10.25 - 15.57 | 12.29 |
| Upside | 540.6% - 873.2% | 668.4% |
| Date | EV/EBITDA |
| 2025-07-02 | 3.41 |
| 2025-07-01 | 3.14 |
| 2025-06-30 | 3.07 |
| 2025-06-27 | 3.14 |
| 2025-06-26 | 3.14 |
| 2025-06-25 | 3.04 |
| 2025-06-24 | 3.02 |
| 2025-06-23 | 3.00 |
| 2025-06-20 | 3.11 |
| 2025-06-18 | 3.17 |
| 2025-06-17 | 3.15 |
| 2025-06-16 | 3.26 |
| 2025-06-13 | 3.02 |
| 2025-06-12 | 2.99 |
| 2025-06-11 | 2.96 |
| 2025-06-10 | 2.96 |
| 2025-06-09 | 3.02 |
| 2025-06-06 | 2.93 |
| 2025-06-05 | 2.74 |
| 2025-06-04 | 2.78 |
| 2025-06-03 | 2.81 |
| 2025-06-02 | 2.73 |
| 2025-05-30 | 2.69 |
| 2025-05-29 | 2.80 |
| 2025-05-28 | 2.88 |
| 2025-05-27 | 2.62 |
| 2025-05-23 | 2.64 |
| 2025-05-22 | 2.66 |
| 2025-05-21 | 2.72 |
| 2025-05-20 | 2.77 |
| 2025-05-19 | 2.77 |
| 2025-05-16 | 2.79 |
| 2025-05-15 | 2.82 |
| 2025-05-14 | 2.88 |
| 2025-05-13 | 2.95 |
| 2025-05-12 | 2.88 |
| 2025-05-09 | 2.91 |
| 2025-05-08 | 3.02 |
| 2025-05-07 | 2.92 |
| 2025-05-06 | 2.88 |
| 2025-05-05 | 2.89 |
| 2025-05-02 | 2.92 |
| 2025-05-01 | 2.89 |
| 2025-04-30 | 2.89 |
| 2025-04-29 | 2.89 |
| 2025-04-28 | 2.92 |
| 2025-04-25 | 2.87 |
| 2025-04-24 | 2.93 |
| 2025-04-23 | 2.97 |
| 2025-04-22 | 2.97 |